Last €0.03 EUR
Change Today 0.00 / 0.00%
Volume 937.0
AGX On Other Exchanges
As of 3:35 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

agennix ag (AGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/2/14 - €0.13
52 Week Low
04/28/14 - €0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AGENNIX AG (AGX)

Related News

No related news articles were found.

agennix ag (AGX) Related Businessweek News

No Related Businessweek News Found

agennix ag (AGX) Details

Agennix AG, a biopharmaceutical company, focuses on the development of therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need primarily in Germany and the United States. The company’s lead product candidate under development includes Talactoferrin, an oral dendritic cell mediated immunotherapy that has completed phase III trial enrollment for the treatment of non-small cell lung cancer; and phase II clinical trial for the treatment of severe sepsis. Its developmental stage products also include topical talactoferrin, which has completed phase IIa clinical trial for the treatment of diabetic foot ulcers; and RGB-286638, a multi-targeted kinase inhibitor that has completed phase I trial for the treatment of solid tumors. The company has manufacturing and supply agreement with DSM Capua S.p.A.; and manufacturing services agreement with Lonza Sales AG. Agennix AG was formerly known as GPC Biotech AG and changed its name to Agennix AG in November, 2009. Agennix AG was founded in 1997 and is based in Heidelberg, Germany. As of May 23, 2013, Agennix AG is in liquidation.

52 Employees
Last Reported Date: 11/30/12
Founded in 1997

agennix ag (AGX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

agennix ag (AGX) Key Developments

Agennix AG Approves Amendments to Articles of Association

Agennix AG announced that at its extraordinary general meeting held on May 22, 2013, the shareholders approved amendments to the articles of association to reduce the size of the Supervisory Board of company from six to three members.

Agennix AG, Special/Extraordinary Shareholders Meeting, May 22, 2013

Agennix AG, Special/Extraordinary Shareholders Meeting, May 22, 2013. Agenda: To consider proposals for the liquidation of the company and a 20:1 reverse stock split.

Agennix AG Postpones Earnings Release Date for Fiscal Year 2012

Agennix AG has postponed expected earnings release date for fiscal 2012, scheduled for March 28, 2013 to a future date to be provided by the company.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGX:GR €0.03 EUR 0.00

AGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGX.
View Industry Companies

Industry Analysis


Industry Average

Valuation AGX Industry Range
No financial data is available for AGX.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENNIX AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at